Tikva Allocell Unveils Groundbreaking CAR T-Cell Research Data at ACR Convergence 2026

In a significant move for biotechnology, Tikva Allocell Pte. Ltd. recently showcased pioneering data at the 2026 ACR Convergence conference, which revolves around the promising use of engineered T-cell therapies for treating systemic lupus erythematosus (SLE). This annual meeting, organized by the American College of Rheumatology, took place in Orlando, Florida, and attracted notable attention from medical professionals and researchers.

Tikva, a Singapore-based biotechnology firm, is at the forefront of developing off-the-shelf T-cell therapies aimed at combating cancer and autoimmune conditions. Their latest research focuses on a novel approach involving CD19 chimeric antigen receptor T-cells (CAR T-cells), specifically the CD19.SB9.CAR-EBVST. This engineered T-cell therapy is designed to potentially treat SLE without the need for lymphodepletion, a medical procedure commonly employed to reduce immune rejection before cell therapies.

Research Highlights

The oral presentation by Dr. Marvin Chew, a senior research scientist at Tikva, revealed compelling findings from preclinical studies conducted on humanized mice models. The studies demonstrated that SB9-armored allogeneic CD19 CAR T-cells exhibited a remarkable nearly 20-fold increase in expansion compared to their unarmored counterparts. Additionally, these armored cells showed sustained depletion of B-cells, critical components of the immune response, which is often dysregulated in individuals with SLE.

In separate evaluations, a mouse model that incorporated immune cells from SLE patients displayed a notable reduction in both B-cell and plasma cell populations, alongside a decrease in circulating autoantibodies, specifically targeting double-stranded DNA (anti-dsDNA). These findings suggest a promising avenue for future therapeutic interventions targeting autoimmune diseases like SLE.

Dr. Chew emphasized that “These preclinical findings support the potential of SB9 armoring to help donor-derived CAR T-cells persist and maintain B-cell depletion in the presence of host allogeneic pressure.” This statement underlines a significant aspect of their research, indicating that the armoring technique could provide a robust solution to the issues posed by immune rejection, which has historically hindered the effectiveness of allogeneic cell therapies.

Implications for SLE Treatment

The implications of Tikva's findings are far-reaching. Ivan Horak, MD, the Founder and CEO of Tikva Allocell, remarked, “These data reinforce the potential of our CD19.SB9.CAR-EBVST program and mark an important step in extending our allogeneic CAR T-cell platform into autoimmune diseases.” By addressing the challenges of immune rejection and the need for lymphodepleting chemotherapy, the research holds significant promise for improving access to cell therapies for SLE patients, a population with pressing unmet medical needs.

The results presented at the conference included three key findings:
1. Enhanced Expansion and Sustained B-cell Depletion: SB9-armored CD19 CAR-EBVSTs exhibited substantial growth and prolonged B-cell depletion in humanized mice.
2. Activity in SLE Patient-derived Models: Evident depletion of crucial immune cells in models that replicate SLE patient conditions.
3. Resistance to Host Immune Pressure: By utilizing SB9 and a constitutive IL-7 receptor, cellular longevity amidst immune response was observed.

The potential for a lymphodepletion-free therapy signifies a landmark breakthrough, as it provides a more accessible solution for patients who might otherwise face barriers related to conventional preparative treatments.

Future Directions

Tikva's strategic focus on expanding their CAR T-cell platform beyond oncological applications to autoimmune disorders is a significant shift in their research narrative. The company continues its commitment to leveraging engineered allogeneic Epstein-Barr virus-specific T cells (EBVSTs) as a foundation for impactful cell therapies.

By pioneering treatments that may eliminate the hurdles of lymphodepleting chemotherapy, Tikva Allocell is laying the groundwork for innovative solutions that could revolutionize care standards for patients with SLE and possibly other autoimmune diseases.

To stay updated on Tikva's advancements and ongoing research initiatives, visit their official website at www.tikvaallocell.com.